Incyte Corporation
Incyte Reports Fourth Quarter and Year-End 2008 Financial Results; Announces 2009 Financial Guidance
Published in Women's Health Weekly, March 5th, 2009
Paul A. Friedman, M.D., Incyte’s President and Chief Executive Officer, stated: “We made significant clinical progress in 2008 including the submission of a Special Protocol Assessment to the FDA for our lead JAK inhibitor, INCB18424, as a treatment for myelofibrosis. As expected, the FDA has made suggestions regarding the proposed protocol to which we plan to respond within the next few weeks. If the FDA agrees with our response we would remain on track to begin our Phase III program in the first...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- American Academy of Neurology
Does gene show link between migraine and stroke or heart attacks? - American Academy of Sleep Medicine
Study finds behavioral link between insomnia and tension-type headaches - Henry Ford Health System
Arab-American women need supplement to boost dangerously low vitamin D levels - Angiogenesis
Reports from University of Nottingham add new data to research in angiogenesis - Angiogenesis
Scientists at Tohoku University publish new data on angiogenesis - Angiology
Scientists at Linkoping University publish research in angiology - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
